质子抑制剂对炎症性肠道疾病的影响:更新的综述
Yu Liang1, Zhen Meng2, Xue-Li Ding3
1Department of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong Province, China.
World journal of gastroenterology
|June 20, 2024
概括
质子抑制剂 (PPI) 可能会影响炎症性肠病 (IBD) 的发展和进展. 本综述探讨了潜在的机制,并强调在给IBD患者处方PPI时需要谨慎.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学 是一个学科.
- 免疫学 免疫学 免疫学
背景情况:
- 炎症性肠病 (IBD) 的病因包括遗传,环境,免疫和微生物因素.
- 质子抑制剂 (PPI) 广泛用于与酸有关的疾病,并经常被处方给IBD患者.
- 新出现的证据表明,PPI使用与IBD发生或恶化之间存在联系.
研究的目的:
- 审查PPI对IBD的潜在影响.
- 分析连接PPI和IBD的潜在生物机制.
- 为了向临床实践提供有关IBD患者PPI处方的信息.
主要方法:
- 关于PPI和IBD最近研究的文献综述.
- 对拟议的病理生理路径进行分析.
- 综合当前关于关联的证据.
主要成果:
- PPI可能会影响肠道微生物组合.
- 胃酸抑制和营养吸收的潜在变化.
- 可能调节与IBD病原发生相关的免疫反应.
结论:
- PPI可能在IBD的发展或进展中发挥作用.
- 需要进一步的研究来阐明这些影响.
- 临床医生在给IBD或IBD风险的人处方PPI时应考虑潜在的风险.
相关概念视频
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
374
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
374
Inflammatory Bowel Disease IV: Pharmacological Management
125
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
125
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
403
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
403
Drugs for Treatment of Ulcerative Colitis in IBD
135
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
135
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
375
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
375


